nach oben

Clinical Reviews in Allergy & Immunology

Erschienen in:

07.08.2020

Clinical Manifestations and Management of Pediatric Behçet’s Disease

verfasst von: Ya-Chiao Hu, Bor-Luen Chiang, Yao-Hsu Yang

Erschienen in: Clinical Reviews in Allergy & Immunology | Ausgabe 2/2021

Einloggen, um Zugang zu erhalten

Abstract

Behçet’s disease (BD) is a chronic, vasculitic disorder affecting all sizes of vessels. The disease rarely onsets at childhood and an early diagnosis is often challenging. Oral ulceration and fever of unknown cause are common initial manifestations that might confuse other inflammatory disorders. The clinical manifestation pattern in pediatric BD is heterogeneous and varies in different genders, ethnicities, and geographic regions. There are also some differences in clinical presentations and prognosis between pediatric and adult BD. The disease also affects children at an extremely young age with mostly benign outcomes compared with that in older children. A limited number of studies reported issues about pediatric BD, let alone studies of children’s treatments. Currently, the recommendation of the treatment in pediatric BD is according to the guideline of adult BD. The heterogeneity of clinical features makes the treatment more complicated. The main goal of the treatment is to control the inflammatory process and prevent recurrences. We will discourse the definition, epidemiology, clinical features, diagnosis, and treatment of pediatric BD in this review.

Sakane T, Takeno M, Suzuki N, Inaba G (1999) Behçet’s disease. N Engl J Med 341(17):1284–1291. https://doi.org/10.1056/NEJM199910213411707CrossRefPubMed

Greco A, De Virgilio A, Ralli M, Ciofalo A, Mancini P, Attanasio G, de Vincentiis M, Lambiase A (2018) Behcet’s disease: new insights into pathophysiology, clinical features and treatment options. Autoimmun Rev 17(6):567–575. https://doi.org/10.1016/j.autrev.2017.12.006CrossRefPubMed

Onder M, Gurer MA (2001) The multiple faces of Behcet’s disease and its aetiological factors. J Eur Acad Dermatol Venereol 15(2):126–136CrossRef

Mundy TM, Miller JJ 3rd (1978) Behcet’s disease presenting as chronic aphthous stomatitis in a child. Pediatrics 62(2):205–208PubMed

Krause I, Uziel Y, Guedj D, Mukamel M, Harel L, Molad Y, Weinberger A (1999) Childhood Behcet’s disease: clinical features and comparison with adult-onset disease. Rheumatology (Oxford) 38(5):457–462CrossRef

Karincaoglu Y, Borlu M, Toker SC, Akman A, Onder M, Gunasti S, Usta A, Kandi B, Durusoy C, Seyhan M, Utas S, Saricaoglu H, Ozden MG, Uzun S, Tursen U, Cicek D, Donmez L, Alpsoy E (2008) Demographic and clinical properties of juvenile-onset Behcet’s disease: a controlled multicenter study. J Am Acad Dermatol 58(4):579–584. https://doi.org/10.1016/j.jaad.2007.10.452CrossRefPubMed

Sungur GK, Hazirolan D, Yalvac I, Ozer PA, Yuksel D, Vural ET, Duman S (2009) Clinical and demographic evaluation of Behcet disease among different paediatric age groups. Br J Ophthalmol 93(1):83–87. https://doi.org/10.1136/bjo.2007.137141CrossRefPubMed

Criteria for diagnosis of Behcet’s disease. International Study Group for Behcet’s Disease (1990) Lancet (London, England) 335 (8697):1078–1080

International Study Group for Behçet's D (1990) Criteria for diagnosis of Behcet’s disease. Lancet 335(8697):1078–1080. https://doi.org/10.1016/0140-6736(90)92643-VCrossRef

10.

International Team for the Revision of the International Criteria for Behcet's D (2014) The International Criteria for Behcet’s Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. J Eur Acad Dermatol Venereol 28(3):338–347. https://doi.org/10.1111/jdv.12107CrossRef

11.

Batu ED, Sonmez HE, Sozeri B, Butbul Aviel Y, Bilginer Y, Ozen S (2017) The performance of different classification criteria in paediatric Behcet's disease. Clin Exp Rheumatol 35 Suppl 108(6):119–123PubMed

12.

Nanthapisal S, Klein NJ, Ambrose N, Eleftheriou D, Brogan PA (2016) Paediatric Behçet’s disease: a UK tertiary centre experience. Clin Rheumatol 35(10):2509–2516. https://doi.org/10.1007/s10067-016-3187-zCrossRefPubMedPubMedCentral

13.

Gallizzi R, Pidone C, Cantarini L, Finetti M, Cattalini M, Filocamo G, Insalaco A, Rigante D, Consolini R, Maggio MC, Civino A, Martino S, Olivieri AN, Fabio G, Pastore S, Mauro A, Sutera D, Trimarchi G, Ruperto N, Gattorno M, Cimaz R (2017) A national cohort study on pediatric Behcet’s disease: cross-sectional data from an Italian registry. Pediatr Rheumatol Online J 15(1):84. https://doi.org/10.1186/s12969-017-0213-xCrossRefPubMedPubMedCentral

14.

Koné-Paut I, Shahram F, Darce-Bello M, Cantarini L, Cimaz R, Gattorno M, Anton J, Hofer M, Chkirate B, Bouayed K, Tugal-Tutkun I, Kuemmerle-Deschner J, Agostini H, Federici S, Arnoux A, Piedvache C, Ozen S (2016) Consensus classification criteria for paediatric Behçet’s disease from a prospective observational cohort: PEDBD. Ann Rheum Dis 75(6):958–964. https://doi.org/10.1136/annrheumdis-2015-208491CrossRefPubMed

15.

Yazici H, Seyahi E, Hatemi G, Yazici Y (2018) Behçet syndrome: a contemporary view. Nat Rev Rheumatol 14:107–119. https://doi.org/10.1038/nrrheum.2017.208CrossRefPubMed

16.

Dilsen N (1996) History and development of Behcet’s disease. Revue du Rhumatisme (English ed) 63(7–8):512–519

17.

Oğuz I, Hizli P, Gönül M (2017) The epidemiology of Behçet’s disease. https://doi.org/10.5772/68055

18.

Citirik M, Berker N, Songur MS, Soykan E, Zilelioglu O (2009) Ocular findings in childhood-onset Behçet disease. J Am Assoc Pediatr Ophthalmol Strabismus 13(4):391–395. https://doi.org/10.1016/j.jaapos.2009.04.016CrossRef

19.

Zouboulis CC, Kotter I, Djawari D, Kirch W, Kohl PK, Ochsendorf FR, Keitel W, Stadler R, Wollina U, Proksch E, Sohnchen R, Weber H, Gollnick HP, Holzle E, Fritz K, Licht T, Orfanos CE (1997) Epidemiological features of Adamantiades-Behcet’s disease in Germany and in Europe. Yonsei Med J 38(6):411–422. https://doi.org/10.3349/ymj.1997.38.6.411CrossRefPubMed

20.

Kone-Paut I, Darce-Bello M, Shahram F, Gattorno M, Cimaz R, Ozen S, Cantarini L, Tugal-Tutktun I, Assaad-Khalil S, Hofer M, Kuemmerle-Deschner J, Benamour S, Al Mayouf S, Pajot C, Anton J, Faye A, Bono W, Nielsen S, Letierce A, Tran TA, Committee P-BIE (2011) Registries in rheumatological and musculoskeletal conditions. Paediatric Behcet’s disease: an international cohort study of 110 patients. One-year follow-up data. Rheumatology (Oxford) 50(1):184–188. https://doi.org/10.1093/rheumatology/keq324CrossRef

21.

Atmaca L, Boyvat A, Yalcindag FN, Atmaca-Sonmez P, Gurler A (2011) Behcet disease in children. Ocul Immunol Inflamm 19(2):103–107. https://doi.org/10.3109/09273948.2011.555592CrossRefPubMed

22.

Davatchi F, Shahram F, Chams-Davatchi C, Shams H, Nadji A, Akhlaghi M, Faezi T, Ghodsi Z, Larimi R, Ashofteh F, Abdollahi BS (2010) Behcet’s disease in Iran: analysis of 6500 cases. Int J Rheum Dis 13(4):367–373. https://doi.org/10.1111/j.1756-185X.2010.01549.xCrossRefPubMed

23.

Hamzaoui A, Jaziri F, Ben Salem T, Ben Ghorbel I, Lamloum M, Smiti Khanfir M, Houman M (2014) Comparison of clinical features of Behcet disease according to age in a Tunisian cohort. Acta Med Iranica 52:748–751

24.

Hu YC, Yang YH, Lin YT, Wang LC, Yu HH, Lee JH, Chiang BL (2019) Clinical manifestations and anti-TNF alpha therapy of juvenile Behcet’s disease in Taiwan. BMC Pediatr 19(1):232. https://doi.org/10.1186/s12887-019-1613-5CrossRefPubMedPubMedCentral

25.

Yazici H, Ugurlu S, Seyahi E (2012) Behçet syndrome: is it one condition? Clin Rev Allergy Immunol 43(3):275–280. https://doi.org/10.1007/s12016-012-8319-xCrossRefPubMed

26.

Kone-Paut I (2016) Behcet’s disease in children, an overview. Pediatr Rheumatol Online J 14(1):10. https://doi.org/10.1186/s12969-016-0070-zCrossRefPubMedPubMedCentral

27.

Vaiopoulos AG, Kanakis MA, Kapsimali V, Vaiopoulos G, Kaklamanis PG, Zouboulis CC (2016) Juvenile Adamantiades-Behcet disease. Dermatology 232(2):129–136. https://doi.org/10.1159/000442667CrossRefPubMed

28.

Borlu M, Ukşal Ü, Ferahbaş A, Evereklioglu C (2006) Clinical features of Behçet's disease in children. Int J Dermatol 45(6):713–716. https://doi.org/10.1111/j.1365-4632.2006.02754.xCrossRefPubMed

29.

Kari JA, Shah V, Dillon MJ (2001) Behcet’s disease in UK children: clinical features and treatment including thalidomide. Rheumatology (Oxford) 40(8):933–938. https://doi.org/10.1093/rheumatology/40.8.933CrossRef

30.

Koné-Paut I, Yurdakul S, Bahabri SA, Shafae N, Ozen S, Özdogan H, Bernard JL (1998) Clinical features of Behçet’s disease in children: an international collaborative study of 86 cases. J Pediatr 132(4):721–725. https://doi.org/10.1016/S0022-3476(98)70368-3CrossRefPubMed

31.

Kesen MR, Goldstein DA, Tessler HH (2008) Uveitis associated with pediatric Behçet disease in the American Midwest. Am J Ophthalmol 146(6):819–827.e812. https://doi.org/10.1016/j.ajo.2008.05.043CrossRefPubMed

32.

Kramer M, Amer R, Mukamel M, Snir M, Jaouni T, Friling R (2009) Uveitis in juvenile Behcet’s disease: clinical course and visual outcome compared with adult patients. Eye (Lond) 23(11):2034–2041. https://doi.org/10.1038/eye.2008.397CrossRef

33.

Tugal-Tutkun I (2011) Pediatric uveitis. J Ophthalmic Vis Res 6(4):259–269PubMedPubMedCentral

34.

Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, Flores-Suarez LF, Gross WL, Guillevin L, Hagen EC, Hoffman GS, Jayne DR, Kallenberg CG, Lamprecht P, Langford CA, Luqmani RA, Mahr AD, Matteson EL, Merkel PA, Ozen S, Pusey CD, Rasmussen N, Rees AJ, Scott DG, Specks U, Stone JH, Takahashi K, Watts RA (2013) 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 65(1):1–11. https://doi.org/10.1002/art.37715CrossRefPubMed

35.

KRUPA B, CIMAZ R, OZEN S, FISCHBACH M, COCHAT P, KONÉ-PAUT I (2011) Pediatric Behçet’s disease and Thromboses. J Rheumatol 38(2):387–390. https://doi.org/10.3899/jrheum.100257CrossRefPubMed

36.

Rottenstreich A, Machol K, Eisenstein EM, Padeh S, Klar A, Livneh A, Berkun Y (2015) Behcet’s disease and cerebral sinus vein thrombosis in children: a case study and review of the literature. Clin Exp Rheumatol 33(6 Suppl 94):S163–S168PubMed

37.

Ozen S, Bilginer Y, Besbas N, Ayaz NA, Bakkaloglu A (2010) Behcet disease: treatment of vascular involvement in children. Eur J Pediatr 169(4):427–430. https://doi.org/10.1007/s00431-009-1040-yCrossRefPubMed

38.

Demir S, Sag E, Kaya Akca U, Hazirolan T, Bilginer Y, Ozen S (2019) The challenge of treating pulmonary Vasculitis in Behçet disease: two pediatric cases. Pediatrics 144(2):e20190162. https://doi.org/10.1542/peds.2019-0162CrossRefPubMed

39.

Demircioğlu Kılıc B, Akbalık Kara M, Ozcelik AA, Ustunsoy H, Balat A (2017) Brachial artery pseudoaneurysm: rare finding in childhood Behcet’s disease. Pediatr Int 59(1):109–110. https://doi.org/10.1111/ped.13149CrossRefPubMed

40.

Seyahi E, Hatemi G, Yazici H, Fresko I, Melikoglu M, Celik S, Yurdakul S, Hamuryudan V (2007) Infliximab in the treatment of hepatic vein thrombosis (Budd-Chiari syndrome) in three patients with Behçet's syndrome. Rheumatology 46(7):1213–1214. https://doi.org/10.1093/rheumatology/kem103CrossRefPubMed

41.

Desbois AC, Wechsler B, Resche-Rigon M, Piette JC, Huong Dle T, Amoura Z, Koskas F, Desseaux K, Cacoub P, Saadoun D (2012) Immunosuppressants reduce venous thrombosis relapse in Behcet’s disease. Arthritis Rheum 64(8):2753–2760. https://doi.org/10.1002/art.34450CrossRefPubMed

42.

Seyahi E, Melikoglu M, Akman C, Hamuryudan V, Ozer H, Hatemi G, Yurdakul S, Tuzun H, Oz B, Yazici H (2012) Pulmonary artery involvement and associated lung disease in Behcet disease: a series of 47 patients. Medicine (Baltimore) 91(1):35–48. https://doi.org/10.1097/MD.0b013e318242ff37CrossRef

43.

Vishwanath V, Wong E, Crystal SC, Robbins MS, Filopoulos M, Lipton RB, Yazici Y, Kister I (2014) Headache in Behçet’s syndrome: review of literature and NYU Behçet’s syndrome center experience. Curr Pain Headache Rep 18(9):445. https://doi.org/10.1007/s11916-014-0445-0CrossRefPubMed

44.

Metreau-Vastel J, Mikaeloff Y, Tardieu M, Kone-Paut I, Tran TA (2010) Neurological involvement in paediatric Behcet’s disease. Neuropediatrics 41(5):228–234. https://doi.org/10.1055/s-0030-1269909CrossRefPubMed

45.

Mora P, Menozzi C, Orsoni JG, Rubino P, Ruffini L, Carta A (2013) Neuro-Behçet’s disease in childhood: a focus on the neuro-ophthalmological features. Orphanet J Rare Dis 8(1):18. https://doi.org/10.1186/1750-1172-8-18CrossRefPubMedPubMedCentral

46.

Uluduz D, Kurtuncu M, Yapici Z, Seyahi E, Kasapcopur O, Ozdogan H, Saip S, Akman-Demir G, Siva A (2011) Clinical characteristics of pediatric-onset neuro-Behcet disease. Neurology 77(21):1900–1905. https://doi.org/10.1212/WNL.0b013e318238edebCrossRefPubMed

47.

Hirohata S, Isshi K, Oguchi H, Ohse T, Haraoka H, Takeuchi A, Hashimoto T (1997) Cerebrospinal fluid interleukin-6 in progressive neuro-Behcet’s syndrome. Clin Immunol Immunopathol 82(1):12–17. https://doi.org/10.1006/clin.1996.4268CrossRefPubMed

48.

Grigg EL, Kane S, Katz S (2012) Mimicry and deception in inflammatory bowel disease and intestinal Behcet disease. Gastroenterol Hepatol 8(2):103–112

49.

Gallizzi R, De Vivo D, Valenti S, Pidone C, Romeo C, Caruso R, Romano C (2017) Intestinal and neurological involvement in Behcet disease: a clinical case. Ital J Pediatr 43(1):33–33. https://doi.org/10.1186/s13052-017-0350-3CrossRefPubMedPubMedCentral

50.

Hung CH, Lee JH, Chen ST, Yang YH, Lin YT, Wang LC, Yu HH, Chiang BL (2013) Young children with Behcet disease have more intestinal involvement. J Pediatr Gastroenterol Nutr 57(2):225–229. https://doi.org/10.1097/MPG.0b013e3182936ec4CrossRefPubMed

51.

Lopalco G, Rigante D, Venerito V, Fabiani C, Franceschini R, Barone M, Lapadula G, Galeazzi M, Frediani B, Iannone F, Cantarini L (2017) Update on the medical management of gastrointestinal Behcet’s disease. Mediat Inflamm 2017:1460491–1460411. https://doi.org/10.1155/2017/1460491CrossRef

52.

Kim DH, Cheon JH (2016) Intestinal Behçet’s disease: a true inflammatory bowel disease or merely an intestinal complication of systemic vasculitis? Yonsei Med J 57(1):22–32. https://doi.org/10.3349/ymj.2016.57.1.22CrossRefPubMed

53.

Valenti S, Gallizzi R, De Vivo D, Romano C (2017) Intestinal Behcet and Crohn’s disease: two sides of the same coin. Pediatr Rheumatol Online J 15(1):33. https://doi.org/10.1186/s12969-017-0162-4CrossRefPubMedPubMedCentral

54.

Kone-Paut I, Geisler I, Wechsler B, Ozen S, Ozdogan H, Rozenbaum M, Touitou I (1999) Familial aggregation in Behcet’s disease: high frequency in siblings and parents of pediatric probands. J Pediatr 135(1):89–93CrossRef

55.

Krause I, Uziel Y, Guedj D, Mukamel M, Molad Y, Amit M, Weinberger A (1998) Mode of presentation and multisystem involvement in Behcet’s disease: the influence of sex and age of disease onset. J Rheumatol 25(8):1566–1569PubMed

56.

Jog S, Patole S, Koh G, Whitehall J (2001) Unusual presentation of neonatal Behcet’s disease. Amer J Perinatol 18(05):287–292. https://doi.org/10.1055/s-2001-16994CrossRef

57.

Fain O, Mathieu E, Lachassinne E, Buisson P, Bodemer C, Gaudelus J, Thomas M (1995) Neonatal behçet's disease. Neonatal Behçet's Dis 98:98–311. https://doi.org/10.1016/S0002-9343(99)80382-9CrossRef

58.

Lewis AM, Priestley LB (1986) Transient neonatal Behçet’s disease. Arch Dis Child 61:805–806. https://doi.org/10.1136/adc.61.8.805CrossRefPubMedPubMedCentral

59.

Thivolet J, Cambazard F, Genvo MF (1982) Maternallytransmitted severe neonatal aphthosis. Ann Dermatol Venereol 109(9):815–816

60.

Fam GA, Siminovitch AK, Carette S, From L (1981) Neonatal Behcet’s Syndrome in an Infant of a Mother with the Disease. Ann Rheum Dis 40:509–512. https://doi.org/10.1136/ard.40.5.509CrossRefPubMedPubMedCentral

61.

Johnson FE, Hawkins MD, Gifford KL, Smidt A (2015) Recurrent Oral and Genital Ulcers in an Infant: Neonatal Presentation of Pediatric Behçet Disease. Pediatr Dermatol 32:714–717. https://doi.org/10.1111/pde.12512CrossRefPubMed

62.

Chang YS, Yang YH, Chiang BL (2011) Neonatal Behcet’s disease without maternal history. Clin Rheumatol 30(12):1641–1645. https://doi.org/10.1007/s10067-011-1830-2CrossRefPubMed

63.

Hatemi G, Christensen R, Bang D, Bodaghi B, Celik AF, Fortune F, Gaudric J, Gul A, Kotter I, Leccese P, Mahr A, Moots R, Ozguler Y, Richter J, Saadoun D, Salvarani C, Scuderi F, Sfikakis PP, Siva A, Stanford M, Tugal-Tutkun I, West R, Yurdakul S, Olivieri I, Yazici H (2018) 2018 update of the EULAR recommendations for the management of Behcet’s syndrome. Ann Rheum Dis 77(6):808–818. https://doi.org/10.1136/annrheumdis-2018-213225CrossRefPubMed

64.

Yurdakul S, Mat C, Tüzün Y, Özyazgan Y, Hamuryudan V, Uysal Ö, Şenocak M, Yazici H (2001) A double-blind trial of colchicine in Behçet’s syndrome. Arthritis Rheum 44(11):2686–2692. https://doi.org/10.1002/1529-0131(200111)44:11<2686::Aid-art448>3.0.Co;2-hCrossRefPubMed

65.

Gholijani N, Ataollahi MR, Samiei A, Aflaki E, Shenavandeh S, Kamali-Sarvestani E (2017) An elevated pro-inflammatory cytokines profile in Behcet’s disease: a multiplex analysis. Immunol Lett 186:46–51. https://doi.org/10.1016/j.imlet.2016.12.001CrossRefPubMed

66.

Burillo-Sanz S, Montes-Cano MA, Garcia-Lozano JR, Ortiz-Fernandez L, Ortego-Centeno N, Garcia-Hernandez FJ, Espinosa G, Grana-Gil G, Sanchez-Burson J, Rosa Julia M, Solans R, Blanco R, Barnosi-Marin AC, Gomez De la Torre R, Fanlo P, Rodriguez-Carballeira M, Rodriguez-Rodriguez L, Camps T, Castaneda S, Alegre-Sancho JJ, Martin J, Gonzalez-Escribano MF (2017) Mutational profile of rare variants in inflammasome-related genes in Behcet disease: a next generation sequencing approach. Sci Rep 7(1):8453. https://doi.org/10.1038/s41598-017-09164-7CrossRefPubMedPubMedCentral

67.

Wakefield D, Lloyd A (1992) The role of cytokines in the pathogenesis of inflammatory eye disease. Cytokine 4(1):1–5. https://doi.org/10.1016/1043-4666(92)90028-pCrossRefPubMed

68.

Calvo-Rio V, Blanco R, Beltran E, Sanchez-Burson J, Mesquida M, Adan A, Hernandez MV, Hernandez Garfella M, Valls Pascual E, Martinez-Costa L, Sellas-Fernandez A, Cordero Coma M, Diaz-Llopis M, Gallego R, Salom D, Garcia Serrano JL, Ortego N, Herreras JM, Fonollosa A, Garcia-Aparicio AM, Maiz O, Blanco A, Torre I, Fernandez-Espartero C, Jovani V, Peiteado-Lopez D, Pato E, Cruz J, Fernandez-Cid C, Aurrecoechea E, Garcia M, Caracuel MA, Montilla C, Atanes A, Hernandez FF, Insua S, Gonzalez-Suarez S, Sanchez-Andrade A, Gamero F, Linares L, Romero-Bueno F, Garcia AJ, Almodovar R, Minguez E, Carrasco Cubero C, Olive A, Vazquez J, Ruiz Moreno O, Jimenez-Zorzo F, Manero J, Munoz Fernandez S, Rueda-Gotor J, Gonzalez-Gay MA (2014) Anti-TNF-alpha therapy in patients with refractory uveitis due to Behcet’s disease: a 1-year follow-up study of 124 patients. Rheumatology (Oxford) 53(12):2223–2231. https://doi.org/10.1093/rheumatology/keu266CrossRef

69.

Vallet H, Riviere S, Sanna A, Deroux A, Moulis G, Addimanda O, Salvarani C, Lambert M, Bielefeld P, Seve P, Sibilia J, Pasquali J, Fraison J, Marie I, Perard L, Bouillet L, Cohen F, Sene D, Schoindre Y, Lidove O, Le Hoang P, Hachulla E, Fain O, Mariette X, Papo T, Wechsler B, Bodaghi B, Rigon MR, Cacoub P, Saadoun D, French Behcet N (2015) Efficacy of anti-TNF alpha in severe and/or refractory Behcet’s disease: multicenter study of 124 patients. J Autoimmun 62:67–74. https://doi.org/10.1016/j.jaut.2015.06.005CrossRefPubMed

70.

Tanida S, Inoue N, Kobayashi K, Naganuma M, Hirai F, Iizuka B, Watanabe K, Mitsuyama K, Inoue T, Ishigatsubo Y, Suzuki Y, Nagahori M, Motoya S, Nakamura S, Arora V, Robinson AM, Thakkar RB, Hibi T (2015) Adalimumab for the treatment of Japanese patients with intestinal Behcet’s disease. Clin Gastroenterol Hepatol 13(5):940–948 e943. https://doi.org/10.1016/j.cgh.2014.08.042CrossRefPubMed

71.

Inoue N, Kobayashi K, Naganuma M, Hirai F, Ozawa M, Arikan D, Huang B, Robinson AM, Thakkar RB, Hibi T (2017) Long-term safety and efficacy of adalimumab for intestinal Behcet’s disease in the open label study following a phase 3 clinical trial. Intest Res 15(3):395–401. https://doi.org/10.5217/ir.2017.15.3.395CrossRefPubMedPubMedCentral

72.

Saulsbury FT, Mann JA (2003) Treatment with infliximab for a child with Behcet’s disease. Arthritis Rheum 49(4):599–600. https://doi.org/10.1002/art.11204CrossRefPubMed

73.

Kaneko U, Kishi T, Kikuchi M, Hara R, Shinoki T, Miyamae T, Imagawa T, Mori M, Yokota S (2010) Two patients with childhood-onset Behcet’s disease successfully treated by anti-tumor necrosis factor therapy. Nihon Rinsho Meneki Gakkai Kaishi 33(3):157–161CrossRef

74.

Watanabe S, Aizawa-Yashiro T, Tsuruga K, Kinjo M, Ito E, Tanaka H (2013) A young girl with refractory intestinal Behcet’s disease: a case report and review of literatures on pediatric cases who received an anti-tumor necrosis factor agent. Rheumatol Int 33(12):3105–3108. https://doi.org/10.1007/s00296-012-2628-5CrossRefPubMed

75.

Evereklioglu C, Borlu M (2008) Sustained remission after infliximab in a child with vasculitis refractory to conventional immunosuppressives including interferon-α. Br J Ophthalmol 92(8):1034. https://doi.org/10.1136/bjo.2007.127522CrossRefPubMed

76.

Cantarini L, Tinazzi I, Caramaschi P, Bellisai F, Brogna A, Galeazzi M (2009) Safety and efficacy of etanercept in children with juvenile-onset Behcet’s disease. Int J Immunopathol Pharmacol 22(2):551–555. https://doi.org/10.1177/039463200902200235CrossRefPubMed

77.

Robinson AB, Gallentine WB, Rabinovich CE (2010) Pediatric neuro-Behcet’s disease responsive to adalimumab. Pediatr Neurol 43(4):291–293. https://doi.org/10.1016/j.pediatrneurol.2010.04.021CrossRefPubMed

78.

Vitale A, Rigante D, Lopalco G, Emmi G, Bianco MT, Galeazzi M, Iannone F, Cantarini L (2016) New therapeutic solutions for Behcet’s syndrome. Expert Opin Investig Drugs 25(7):827–840. https://doi.org/10.1080/13543784.2016.1181751CrossRefPubMed

79.

Essayan DM, Fox CC, Levi-Schaffer F, Alam R, Rosenwasser LJ (1998) Biologic activities of IL-1 and its role in human disease. J Allergy Clin Immunol 102(3):344–350. https://doi.org/10.1016/S0091-6749(98)70118-6CrossRef

80.

Farivar S, Hassani M, Shiari R (2014) Interleukin-1 as a key factor in the development of inflammatory diseases. Arch Pediatr Infect Dis 2(4):e18177. https://doi.org/10.5812/pedinfect.18177CrossRef

81.

Caso F, Costa L, Rigante D, Lucherini OM, Caso P, Bascherini V, Frediani B, Cimaz R, Marrani E, Nieves-Martin L, Atteno M, Raffaele CG, Tarantino G, Galeazzi M, Punzi L, Cantarini L (2014) Biological treatments in Behcet’s disease: beyond anti-TNF therapy. Mediat Inflamm 2014:107421–107414. https://doi.org/10.1155/2014/107421CrossRef

82.

Caso F, Iaccarino L, Bettio S, Ometto F, Costa L, Punzi L, Doria A (2013) Refractory pemphigus foliaceus and Behcet’s disease successfully treated with tocilizumab. Immunol Res 56(2–3):390–397. https://doi.org/10.1007/s12026-013-8411-1CrossRefPubMed

83.

Diamantopoulos AP, Hatemi G (2013) Lack of efficacy of tocilizumab in mucocutaneous Behcet’s syndrome: report of two cases. Rheumatology (Oxford) 52(10):1923–1924. https://doi.org/10.1093/rheumatology/ket130CrossRef

84.

Deroux A, Chiquet C, Bouillet L (2016) Tocilizumab in severe and refractory Behcet's disease: four cases and literature review. Semin Arthritis Rheum 45(6):733–737. https://doi.org/10.1016/j.semarthrit.2015.11.012CrossRefPubMed

Titel: Clinical Manifestations and Management of Pediatric Behçet’s Disease
verfasst von: Ya-Chiao Hu
Bor-Luen Chiang
Yao-Hsu Yang
Publikationsdatum: 07.08.2020
Verlag: Springer US
Erschienen in: Clinical Reviews in Allergy & Immunology / Ausgabe 2/2021
Print ISSN: 1080-0549
Elektronische ISSN: 1559-0267
DOI: https://doi.org/10.1007/s12016-020-08809-2

Neu im Fachgebiet HNO

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Hörschwäche erhöht Demenzrisiko unabhängig von Beta-Amyloid

29.05.2024 Hörstörungen Nachrichten

Hört jemand im Alter schlecht, nimmt das Hirn- und Hippocampusvolumen besonders schnell ab, was auch mit einem beschleunigten kognitiven Abbau einhergeht. Und diese Prozesse scheinen sich unabhängig von der Amyloidablagerung zu ereignen.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

16.05.2024 Pädiatrische Allergologie Nachrichten

Die große Mehrheit der vermeintlichen Penicillinallergien sind keine. Da das „Etikett“ Betalaktam-Allergie oft schon in der Kindheit erworben wird, kann ein frühzeitiges Delabeling lebenslange Vorteile bringen. Ein Team von Pädiaterinnen und Pädiatern aus Kanada stellt vor, wie sie dabei vorgehen.

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Clinical Manifestations and Management of Pediatric Behçet’s Disease

Abstract

Neu im Fachgebiet HNO

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Hörschwäche erhöht Demenzrisiko unabhängig von Beta-Amyloid

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

Update HNO

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2021

Comparison of Diagnostic Criteria for Common Variable Immunodeficiency Disorders (CVID) in the New Zealand CVID Cohort Study

Chronic Granulomatous Disease: a Comprehensive Review

Treatments for Childhood Atopic Dermatitis: an Update on Emerging Therapies

Inflammasomes and Childhood Autoimmune Diseases: A Review of Current Knowledge

Cutaneous Vasculitis: Review on Diagnosis and Clinicopathologic Correlations

A Review of Neutrophil Extracellular Traps (NETs) in Disease: Potential Anti-NETs Therapeutics

Neu im Fachgebiet HNO

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Hörschwäche erhöht Demenzrisiko unabhängig von Beta-Amyloid

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

Update HNO